Karen Daily, DO - Research

Research at a glance

Top areas of exploration

Breast Neoplasms , 10 publications
Neoplasms , 4 publications
Neoplasm Recurrence, Local , 3 publications
Antineoplastic Combined Chemotherapy Protocols , 3 publications

Research activity

41 publications

438 citations

Why is this important?

Active clinical trials

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 * early breast cancer with intermediate or high risk for disease recurrence who completed definitive鈥�

Investigator: Karen Daily
Status: Accepting Candidates
Ages: 18 Years - 130 Years
Sexes: All

My publications

41 publications

2023

Clinical characteristics, prognostic factors, and long-term outcomes associated with epithelial malignancies of the thymus: A 20-year single-institution experience.

Cancer reports (Hoboken, N.J.)

鈥�

2023

Immune-mediated herb-induced liver injury: a potential association with herbal artemisinin use as supported by the updated RUCAM.

BMJ case reports

鈥�

2023

Systemic absorption of intrathecal methotrexate.

BMJ case reports

鈥�

2022

BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer

Journal of Clinical Oncology

2022

Does definitive local therapy have a role in select HER2+鈥塪e novo metastatic breast cancer patients treated with dual anti-HER2 blockade?

Breast Cancer Research and Treatment

网红黑料

Karen Daily, DO : Research

Research at a glance

Top areas of exploration

Research activity

Active clinical trials

My publications

Clinical characteristics, prognostic factors, and long-term outcomes associated with epithelial malignancies of the thymus: A 20-year single-institution experience.

Immune-mediated herb-induced liver injury: a potential association with herbal artemisinin use as supported by the updated RUCAM.

Systemic absorption of intrathecal methotrexate.

BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer

Does definitive local therapy have a role in select HER2+鈥塪e novo metastatic breast cancer patients treated with dual anti-HER2 blockade?

网红黑料

Research at a glance

Top areas of exploration

Research activity

Active clinical trials

My publications

Filter publications

Clinical characteristics, prognostic factors, and long-term outcomes associated with epithelial malignancies of the thymus: A 20-year single-institution experience.

Immune-mediated herb-induced liver injury: a potential association with herbal artemisinin use as supported by the updated RUCAM.

Systemic absorption of intrathecal methotrexate.

BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer

Does definitive local therapy have a role in select HER2+鈥塪e novo metastatic breast cancer patients treated with dual anti-HER2 blockade?